Close Menu Phone
ABL
Menu

ABL advises ASX-listed Probiotec on acquisition of leading pharmaceutical business

Corporate and M&A, Property & Development, Workplace Advisory
Foil medicine pill packet
Arnold Bloch Leibler has advised long-standing client, ASX-listed Probiotec Limited, on its acquisition of leading pharmaceutical business Australian Blister Sealing (ABS).

Probiotec is a manufacturer, marketer and distributor of a diverse, high quality range of prescription and over-the-counter pharmaceuticals and complementary medicines. ABS is a 40 year old pharmaceutical and consumer products contract packer, with the capability to pack a wide range of formats for the pharmaceutical, cosmetic and food industries.
 
Led by Corporate and M&A Partner Jeremy Lanzer, the cross-practice team advising Probiotec included Anna Sandiford and Karri Walker (Corporate and M&A), Gia Cari, Ben Worth and Sam Scheinberg (Property) and Bridget Little and Emily Gray (Workplace Advisory).

Jeremy commented on the transaction, which is due to be completed in the coming months: “Following Probiotec’s successful acquisition of pharmaceutical packing business South Pack Laboratories in 2017, this transaction demonstrates Probiotec’s ongoing strategy of increasing its core manufacturing capabilities, scale and reach throughout the industry. ABL is privileged to continue partnering with Probiotec and to celebrate its ongoing success.”

About Arnold Bloch Leibler 

Arnold Bloch Leibler is a premium Australian commercial law firm renowned for advising clients on their most important transactions, commercial issues and disputes. From offices in Melbourne and Sydney, the firm provides advice to a diverse range of entrepreneurial Australian listed companies, family businesses, high-net-worth individuals and international corporations. The firm also has a dedicated pro bono practice providing advice on social, environmental and cultural issues to more than 150 charitable and not-for-profit organisations.

Read next